Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | -1.12% | +3.68% | +37.17% |
Financials (USD)
Sales 2024 * | 334M | Sales 2025 * | 390M | Capitalization | 1.44B |
---|---|---|---|---|---|
Net income 2024 * | 67M | Net income 2025 * | 114M | EV / Sales 2024 * | 4.31 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.68 x |
P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
12.4
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.46% |
Latest transcript on ADMA Biologics, Inc.
1 day | -1.12% | ||
1 week | +3.68% | ||
Current month | -6.06% | ||
1 month | -1.43% | ||
3 months | +17.20% | ||
6 months | +96.20% | ||
Current year | +37.17% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +4.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 6.2 | -1.12% | 2,301,644 |
24-04-19 | 6.27 | +1.13% | 3,411,885 |
24-04-18 | 6.2 | +2.65% | 2,983,796 |
24-04-17 | 6.04 | -1.95% | 1,711,815 |
24-04-16 | 6.16 | +3.01% | 1,764,248 |
Delayed Quote Nasdaq, April 22, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.17% | 1.44B | |
-2.72% | 85.68B | |
+5.53% | 41.4B | |
-24.99% | 28.22B | |
+54.63% | 24.64B | |
-7.19% | 16.98B | |
-34.20% | 13.29B | |
-17.31% | 11.66B | |
-11.43% | 11.65B | |
-1.57% | 8.18B |
- Stock Market
- Equities
- ADMA Stock